Incremental net monetary benefit of herpes zoster vaccination: a systematic review and meta-analysis of cost-effectiveness evidence

CONCLUSIONS: RZV may be cost-effective for vaccination in ages of 60-79 years for both SP and TPP perspectives, while ZVL might be cost-effective in some age groups, but results are not robust.PMID:34791974 | DOI:10.1080/13696998.2021.2008195

Source: Journal of Medical Economics - November 18, 2021 Category: Health Management Authors: Sariya Udayachalerm Maranda G Renouard Thunyarat Anothaisintawee Ammarin Thakkinstian Sajesh K Veettil Nathorn Chaiyakunapruk Source Type: research